This Article Full Text Full Text (PDF) All Versions of this Article: 97/9/922    most recent 01.RES.0000187467.67684.43v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ali, K. Articles by Rader, D. J. Search for Related Content PubMed PubMed Citation Articles by Ali, K. Articles by Rader, D. J. Related Collections Animal models of human disease Pathophysiology Growth factors/cytokines Lipid and lipoprotein metabolism Mechanism of atherosclerosis/growth factors

Apolipoprotein E Suppresses the Type I Inflammatory Response In Vivo

From the Institute for Translational Medicine and Therapeutics and Department of Medicine (K.A., D.J.R.) and Immunology Graduate Group (M.M.), University of Pennsylvania School of Medicine, Philadelphia; Wistar Institute (M.M., E.P.), Philadelphia; and The Ludwig Institute for Cancer Research, Philadelphia, Penn.

Correspondence to Dr Daniel Rader, University of Pennsylvania School of Medicine, Center for Experimental Therapeutics, 421 Curie Blvd, 654 BRBII/III Labs, Philadelphia, PA, 19104-6160. E-mail rader{at}mail.med.upenn.edu

Apolipoprotein E (apoE) is synthesized in the liver and in macrophages, and it has antiatherogenic properties that are mediated, at least in part, through the regulation of plasma cholesterol homeostasis. Previous data suggest that apoE also has antiinflammatory properties that may contribute to protection against atherosclerosis independent of its role in lipid metabolism. In this study, apoE knockout and C57BL/6 mice were stimulated with low-dose lipopolysaccharide (LPS) and other Toll-like receptor (TLR) agonists. We show that apoE modulates the systemic type I inflammatory response in vivo. The proinflammatory cytokines tumor necrosis factor , interleukin (IL)-6, IL-12, and interferon- were upregulated to a significantly greater extent in apoE-deficient mice than in wild-type mice at both the mRNA and protein levels following administration of LPS. In contrast, hypercholesterolemic low-density lipoprotein receptor/apobec-1 double knockout mice had a similar cytokine response as wild-type mice, eliminating hypercholesterolemia as a cause for the exaggerated cytokine response. Importantly, reconstitution of apoE expression in the liver of apoE-deficient mice normalized the LPS-induced plasma protein levels of IL-12p40. Furthermore, there was selective upregulation of plasma IL-12 in apoE knockout mice by a TLR3 agonist, poly I:C, but not by other TLR agonists, CpG oligonucleotide or Toxoplasma gondii antigen. This implies that apoE selectively regulates TLR4- and TLR3-mediated signaling of IL-12 production. These results indicate that apoE modulates the T helper-1–type immune response in vivo by modulating IL-12 production.

Key Words: apolipoprotein E • inflammation • interleukin-12 • lipopolysaccharide • T helper-1

This article has been cited by other articles:

				M. Ni, Y. Wang, M. Zhang, P. F. Zhang, S. F. Ding, C. X. Liu, X. L. Liu, Y. X. Zhao, and Y. Zhang Atherosclerotic plaque disruption induced by stress and lipopolysaccharide in apolipoprotein E knockout mice Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1598 - H1606. [Abstract] [Full Text] [PDF]

				G. S. Getz and C. A. Reardon Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall J. Lipid Res., April 1, 2009; 50(Supplement): S156 - S161. [Abstract] [Full Text] [PDF]

				L. Li, P. A. Thompson, and R. L. Kitchens Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: role of hepatic LDL receptors J. Lipid Res., August 1, 2008; 49(8): 1782 - 1793. [Abstract] [Full Text] [PDF]

				M. Kockx, W. Jessup, and L. Kritharides Regulation of Endogenous Apolipoprotein E Secretion by Macrophages Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1060 - 1067. [Abstract] [Full Text] [PDF]

				M. Mayr, A. Zampetaki, A. Sidibe, U. Mayr, X. Yin, A. I. De Souza, Y.-L. Chung, B. Madhu, P. H. Quax, Y. Hu, et al. Proteomic and Metabolomic Analysis of Smooth Muscle Cells Derived From the Arterial Media and Adventitial Progenitors of Apolipoprotein E-Deficient Mice Circ. Res., May 9, 2008; 102(9): 1046 - 1056. [Abstract] [Full Text] [PDF]

				S. M. Hofmann, D. Perez-Tilve, T. M. Greer, B. A. Coburn, E. Grant, J. E. Basford, M. H. Tschop, and D. Y. Hui Defective Lipid Delivery Modulates Glucose Tolerance and Metabolic Response to Diet in Apolipoprotein E Deficient Mice Diabetes, January 1, 2008; 57(1): 5 - 12. [Abstract] [Full Text] [PDF]

				S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra Mouse Models for Atherosclerosis and Pharmaceutical Modifiers Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1706 - 1721. [Abstract] [Full Text] [PDF]

				D. Gozal, O. S. Capdevila, L. Kheirandish-Gozal, and V. M. Crabtree APOE {varepsilon}4 allele, cognitive dysfunction, and obstructive sleep apnea in children Neurology, July 17, 2007; 69(3): 243 - 249. [Abstract] [Full Text] [PDF]

				M. Ranalletta, N. Wang, S. Han, L. Yvan-Charvet, C. Welch, and A. R. Tall Decreased Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice Transplanted With Abcg1-/- Bone Marrow Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2308 - 2315. [Abstract] [Full Text] [PDF]

				T. Sasaki, M. Kuzuya, K. Nakamura, X. W. Cheng, T. Shibata, K. Sato, and A. Iguchi A Simple Method of Plaque Rupture Induction in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1304 - 1309. [Abstract] [Full Text] [PDF]